Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Innovation: Balancing Benefi ts and Costs
- European Union
- High-Level Group on Innovation and the Provision of Medicines (G10
Medicines Group)
- High-Level Pharmaceutical Forum
- France
- Standard Price-Setting Procedure
- Price Setting for Innovative Drugs
- Renewal of Pricing and Reimbursement
- Germany
- Reference Pricing
- Prescribing Budgets
- Health Technology Assessment
- New Restrictions on the Use of Costly Drugs
- Italy
- Spain
- Price Setting
- Prior Authorization
- More Selective Funding of Medicines
- United Kingdom
- Proposal to Replace the Pharmaceutical Price Regulation Scheme
- National Institute for Clinical Excellence
- Review of Variations in the Use of NICE-Approved Cancer Drugs
- Patient Action Against Lack of Access to Certain Drugs
- Accelerated NICE Appraisal Process
- Japan
- Initial Pricing of Branded Prescription Drugs
- Similar-Effi cacy Comparison Methods
- Cost Calculation Method
- Price Premiums
- United States
- Formulary Decision Making in the Private Sector
- Medicare Sponsorship of Health Economic Research
- Outlook and Implications for the Pharmaceutical Industry
Tables:
- 1. Methods Used for Pricing New Drugs in Japan, June 2002-March 2007
- 2. Hierarchy of National Health Insurance Price Premiums in Japan
- 3. Number of New Drugs Awarded Price Premiums for Therapeutic Advances,
June 2002-March 2007
- 4. U.S. Employers' Views on Strategies to Increase Prescription Drug
Benefit Value
- 5. U.S. Employers' Views on Strategies to Increase Prescription Drug
Benefit Value
Figures:
- 1. New Drugs' Share of Total Pharmaceutical Expenditures in Major Markets,
2001-2004
- 2. Percentage of Drugs Awarded Various SMR Ratings in France
- 3. Percentage of Drugs Awarded Various ASMR Ratings in France
- 4. Criteria for Determining the Pricing Method Used for New Prescription
Drugs in Japan
|
Related Report
|
View Cart
